Terns Pharmaceuticals Files 2024 10-K

Ticker: TERN · Form: 10-K · Filed: Mar 20, 2025 · CIK: 1831363

Sentiment: neutral

Topics: 10-K, pharmaceuticals, financials

TL;DR

Terns Pharma 2024 10-K is in. Check financials & biz ops.

AI Summary

Terns Pharmaceuticals, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The filing details its business operations, financial condition, and risk factors. Key financial data and operational segments are outlined, including information on employee stock options and various agreements.

Why It Matters

This filing provides investors and the public with a comprehensive overview of Terns Pharmaceuticals' financial health and strategic direction for the fiscal year 2024, crucial for understanding the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Terns is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Terns Pharmaceuticals, Inc. as described in the 10-K?

The filing indicates Terns Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry (SIC code 2834).

When did Terns Pharmaceuticals, Inc. file its 10-K report?

Terns Pharmaceuticals, Inc. filed its 10-K report on March 20, 2025.

What is the fiscal year end for Terns Pharmaceuticals, Inc.?

The fiscal year end for Terns Pharmaceuticals, Inc. is December 31.

Where is Terns Pharmaceuticals, Inc. located?

The company's business and mailing address is 1065 East Hillsdale Blvd., Suite 100, Foster City, CA 94404.

Are there any specific agreements mentioned in the filing data provided?

Yes, the filing data mentions 'HansohOptionAndLicenseAgreementMember' and 'AssignmentAgreementMember'.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding Terns Pharmaceuticals, Inc. (TERN).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing